Highlights Telix Pharmaceuticals Limited

Stocks

TLX

AU000000TLX2

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 11:46:23 11/06/2026 am IST			5-day change	1st Jan Change
13.47 ^AUD	-0.44%		+4.50%	+20.27%

03/06	Telix Pharmaceuticals, United Imaging Healthcare Sign MOU for US Theranostics Collaboration; Shares Down 3%	MT
03/06	Telix Pharmaceuticals, United Imaging Healthcare Sign MOU for US Theranostics Collaboration	MT

Highlights

03/06	Telix Pharmaceuticals, United Imaging Healthcare Sign MOU for US Theranostics Collaboration; Shares Down 3%	MT
03/06	Telix Pharmaceuticals, United Imaging Healthcare Sign MOU for US Theranostics Collaboration	MT
02/06	Telix Pharmaceuticals Limited and United Imaging Healthcare North America, Inc. Announce Strategic Theranostics Collaboration	CI
02/06	Telix Pharmaceuticals Limited Presents Part 1 Data from Prostact Global Phase 3 Study of Tlx591-Tx in Metastatic Castration-Resistant Prostate Cancer	CI
21/05	Telix Pharmaceuticals Limited Affirms Group Earnings Guidance for the Full Year 2026	CI
19/05	Telix Pharmaceuticals Limited Completes Enrolment and Confirms Dosing in Ipax-2 Study of Tlx101-Tx in First-Line Glioblastoma	CI
18/05	Telix Pharmaceuticals Shares Fall 3% After Entering Collaboration to Explore Prostate Cancer Imaging in New Treatment Approaches	MT
15/05	Telix Pharmaceuticals Limited, EDAP TMS S.A., Profound Medical Corp. Enter Strategic Collaboration To Explore PSMA-PET Imaging In Prostate Cancer Treatment	CI
14/05	EDAP TMS S.A. and Telix Pharmaceuticals Limited Announce Collaboration Focused on Robotic HIFU and Theranostics in Prostate Cancer	CI
05/05	Telix Pharmaceuticals Limited Announces New Analysis of Tlx250-Px Phase 3 Zircon Trial Data	CI
01/05	Telix Pharmaceuticals says TLX101-PX (Pixlumi®) MAA accepted in Europe	RE
01/05	Telix Pharmaceuticals Limited Announces Acceptance Of Marketing Authorization Application For TLX101-Px In Europe	CI
01/05	Telix Says Marketing Authorization Application for Glioma Imaging Candidate Accepted for Review in Europe; Shares Up 3%	MT
30/04	Telix Pharmaceuticals Limited Presents Initial Dosimetry Data For TLX597-Tx In Prostate Cancer	CI
23/04	Telix Pharmaceuticals Settles Issue of $600 Million Convertible Notes	MT
23/04	Telix Pharmaceuticals announces settlement of $600m convertible bonds	RE
17/04	Telix Pharmaceuticals Says JPMorgan Increases Stake	MT
15/04	Telix Pharmaceuticals Limited Doses First Patient in Phase 3 Ipax-Bright Trial of Tlx101-Tx for Recurrent Glioblastoma	CI
15/04	Telix Pharmaceuticals Upsizes Convertible Notes Due 2031 to $600 Million	MT
13/04	Regeneron Pharmaceuticals, Inc. and Telix Pharmaceuticals Limited Announce Strategic Radiopharma Collaboration	CI
13/04	Telix Pharmaceuticals' Pipeline Validated by Regeneron Deal, Citi Says	MT
13/04	Telix and Regeneron announce radiopharma collaboration	RE
13/04	Telix Pharmaceuticals, Regeneron Form Radiopharmaceutical Partnership	MT
10/04	Telix Pharmaceuticals Limited Announces FDA Acceptance Of Resubmitted New Drug Application For TLX101-Px1 (Pixclara®)	CI
10/04	Telix Pharmaceuticals Says US FDA Accepts New Drug Application for Brain Cancer Imaging Agent	MT